Literature DB >> 12902496

Recombinant TCR ligand induces early TCR signaling and a unique pattern of downstream activation.

Chunhe Wang1, Jeffery L Mooney, Roberto Meza-Romero, Yuan K Chou, Jianya Huan, Arthur A Vandenbark, Halina Offner, Gregory G Burrows.   

Abstract

Recombinant TCR ligands (RTLs) consisting of covalently linked alpha(1) and beta(1) domains of MHC class II molecules tethered to specific antigenic peptides represent minimal TCR ligands. In a previous study we reported that the rat RTL201 construct, containing RT1.B MHC class II domains covalently coupled to the encephalitogenic guinea pig myelin basic protein (Gp-MBP(72-89)) peptide, could prevent and treat actively and passively induced experimental autoimmune encephalomyelitis in vivo by selectively inhibiting Gp-MBP(72-89) peptide-specific CD4(+) T cells. To evaluate the inhibitory signaling pathway, we tested the effects of immobilized RTL201 on T cell activation of the Gp-MBP(72-89)-specific A1 T cell hybridoma. Activation was exquisitely Ag-specific and could not be induced by RTL200 containing the rat MBP(72-89) peptide that differed by a threonine for serine substitution at position 80. Partial activation by RTL201 included a CD3zeta p23/p21 ratio shift, ZAP-70 phosphorylation, calcium mobilization, NFAT activation, and transient IL-2 production. In comparison, anti-CD3epsilon treatment produced stronger activation of these cellular events with additional activation of NF-kappaB and extracellular signal-regulated kinases as well as long term increased IL-2 production. These results demonstrate that RTLs can bind directly to the TCR and modify T cell behavior through a partial activation mechanism, triggering specific downstream signaling events that deplete intracellular calcium stores without fully activating T cells. The resulting Ag-specific activation of the transcription factor NFAT uncoupled from the activation of NF-kappaB or extracellular signal-regulated kinases constitutes a unique downstream activation pattern that accounts for the inhibitory effects of RTL on encephalitogenic CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902496     DOI: 10.4049/jimmunol.171.4.1934

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

Review 1.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

Review 2.  Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.

Authors:  Halina Offner; Sushmita Sinha; Chunhe Wang; Gregory G Burrows; Arthur A Vandenbark
Journal:  Rev Neurosci       Date:  2008       Impact factor: 4.353

Review 3.  Ca2+ signaling in airway epithelial cells facilitates leukocyte recruitment and transepithelial migration.

Authors:  Jarin Chun; Alice Prince
Journal:  J Leukoc Biol       Date:  2009-07-15       Impact factor: 4.962

4.  Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.

Authors:  Wenbin Zhu; Nicole L Libal; Amanda Casper; Sheetal Bodhankar; Halina Offner; Nabil J Alkayed
Journal:  Transl Stroke Res       Date:  2014-06-24       Impact factor: 6.829

5.  Rationally designed mutations convert complexes of human recombinant T cell receptor ligands into monomers that retain biological activity.

Authors:  Jianya Y Huan; Roberto Meza-Romero; Jeffery L Mooney; Yuan K Chou; David M Edwards; Cathleen Rich; Jason M Link; Arthur A Vandenbark; Dennis N Bourdette; Hans-Peter Bächinger; Gregory G Burrows
Journal:  J Chem Technol Biotechnol       Date:  2004-10-12       Impact factor: 3.174

6.  Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.

Authors:  Chunhe Wang; Bruce G Gold; Laurie J Kaler; Xiaolin Yu; Michael E Afentoulis; Gregory G Burrows; Arthur A Vandenbark; Dennis N Bourdette; Halina Offner
Journal:  J Neurochem       Date:  2006-08-03       Impact factor: 5.372

7.  DRα1-MOG-35-55 Reduces Permanent Ischemic Brain Injury.

Authors:  Jianyi Wang; Qing Ye; Jing Xu; Gil Benedek; Haiyue Zhang; Yuanyuan Yang; Huan Liu; Roberto Meza-Romero; Arthur A Vandenbark; Halina Offner; Yanqin Gao
Journal:  Transl Stroke Res       Date:  2016-12-17       Impact factor: 6.829

8.  Recombinant T cell receptor ligand treats experimental stroke.

Authors:  Sandhya Subramanian; Bing Zhang; Yasuharu Kosaka; Gregory G Burrows; Marjorie R Grafe; Arthur A Vandenbark; Patricia D Hurn; Halina Offner
Journal:  Stroke       Date:  2009-05-14       Impact factor: 7.914

9.  Characterization of human platelet binding of recombinant T cell receptor ligand.

Authors:  Asako Itakura; Joseph E Aslan; Sushmita Sinha; Tara C White-Adams; Ishan A Patel; Roberto Meza-Romero; Arthur A Vandenbark; Gregory G Burrows; Halina Offner; Owen Jt McCarty
Journal:  J Neuroinflammation       Date:  2010-11-08       Impact factor: 8.322

10.  Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG.

Authors:  Sushmita Sinha; Sandhya Subramanian; Ashley Emerson-Webber; Maren Lindner; Gregory G Burrows; Marjorie Grafe; Christopher Linington; Arthur A Vandenbark; Claude C A Bernard; Halina Offner
Journal:  J Neuroimmune Pharmacol       Date:  2009-09-30       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.